Substance / Medication

Benperidol

Overview

Active Ingredient
benperidol
RxNorm CUI
1373

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Benperidol for schizophrenia.
Leucht S, Hartung B · Cochrane Database Syst Rev · 2005
PMID: 15846648Meta-AnalysisFull text (PMC)
Benperidol for schizophrenia.
Leucht S, Hartung B · Cochrane Database Syst Rev · 2002
PMID: 11869652Meta-Analysis
Influence of intravenous administration of the antipsychotic drug benperidol on the QT interval.
Schmidt Alexander, Fischer Peter, Wally Beate et al. · Neuropsychiatr · 2017
PMID: 28791627Observational
A comparison of D2 receptor specific binding in obese and normal-weight individuals using PET with (N-[(11)C]methyl)benperidol.
Eisenstein Sarah A, Antenor-Dorsey Jo Ann V, Gredysa Danuta M et al. · Synapse · 2013
PMID: 23650017ObservationalFull text (PMC)
Validation of the reference tissue model for estimation of dopaminergic D2-like receptor binding with [18F](N-methyl)benperidol in humans.
Antenor-Dorsey Jo Ann V, Markham Joanne, Moerlein Stephen M et al. · Nucl Med Biol · 2008
PMID: 18355689ObservationalFull text (PMC)
Complete dopamine D2 receptor occupancy without extrapyramidal side effects under benperidol.
Schönfeldt-Lecuona Carlos, Juengling Freimut D, Connemann Bernhard J et al. · J Clin Psychopharmacol · 2004
PMID: 14709957Case Report
Characterization of extrastriatal D2 in vivo specific binding of [¹⁸F](N-methyl)benperidol using PET.
Eisenstein Sarah A, Koller Jon M, Piccirillo Marilyn et al. · Synapse · 2012
PMID: 22535514OtherFull text (PMC)
Radiation dosimetry of N-([11C]methyl)benperidol as determined by whole-body PET imaging of primates.
Antenor-Dorsey Jo Ann V, Laforest Richard, Moerlein Stephen M et al. · Eur J Nucl Med Mol Imaging · 2008
PMID: 18071701PreclinicalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Benperidol (substance)
SNOMED CT
391820006
UMLS CUI
C0005013
RxNorm CUI
1373

Clinical Data

This intervention maps to 10 entities in the Healos knowledge graph.

5
Conditions
1
Biomarkers
2
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Benperidol — Conditions, Biomarkers & Specialists | Healos | Ltrl